Company Focus
Alnylam Pharmaceuticals
Latest Alnylam Pharmaceuticals News
Pharmaceutical
The UK subsidiary Alnylam welcomed positive Final Draft Guidance issued by the National Institute for Clinical Health and care Excellence (NICE) has recommending the firm’s Amvuttra (vutrisiran) for eligible adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in England and Wales. 21 November 2025
Related News
Insights
Company Spotlight
A clinical‑stage biotech company headquartered in Antwerp, Belgium, developing organ‑restricted therapies for fibrotic disease.
Latest News & Features of interest to Alnylam Pharmaceuticals
Pharmaceutical
Praxis Precision Medicines surged 35% with shares reaching a value of $260, their highest value since the beginning of 2022. Current market cap is ~$6.5 billion, after EMBOLD study success and strong pipeline progress, reaching its highest valuation since early 2022. 6 December 2025
Biotechnology
Swiss immunotherapy firm Neurimmune announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with UK pharma major AstraZeneca’s Alexion, AstraZeneca Rare Disease by entering into an exclusive global collaboration and license agreement to develop NI009. 5 December 2025
Biotechnology
Shares of US drug developer Denali Therapeutics closed up 5.8% at $20.11 yesterday, after it announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa with Royalty Pharma. 5 December 2025
Biotechnology
A new Australian biotech, Evinco Therapeutics, has launched in Melbourne to advance immune-based treatments for Alzheimer’s disease. The private spin-out from Cartherics will focus on extracellular vesicles taken from natural killer cells and delivered intranasally, aiming for a simpler route into the brain. The company is raising funds to support early proof-of-concept work. 4 December 2025
Biotechnology
Teva Pharmaceutical Industries has announced the findings from the final analysis of the real-world pan-European PEARL Phase IV migraine prevention study. 3 December 2025
Biotechnology
Swiss late-stage biotech Pharvaris saw its shares rise 17% to $28.24 today, as it announced RAPIDe-3 pivotal data confirming the potential of deucrictibant’s differentiated profile for the on-demand treatment (ODT) of hereditary angioedema (HAE) attacks. 3 December 2025
Pharmaceutical
Taiwanese biotech Formosa Pharmaceuticals has signed an exclusive agreement with Singapore-based Rxilient Medical to commercialize APP13007 (clobetasol propionate) in Indonesia, the Philippines, Singapore and Thailand. 3 December 2025
Biotechnology
Japanese drugmaker Eisai and US biotech Biogen announced new data confirming the pharmacological effect of Leqembi (lecanemab) were presented at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference. 3 December 2025
Pharmaceutical
GlobalData expects the chronic hepatitis B therapeutics market across major markets to climb from $1.5 billion in 2024 to $3.2 billion in 2034. The projection reflects rising investment in functional cure candidates, which could shift treatment away from long-term antiviral suppression. 3 December 2025
Biotechnology
Axoltis Pharma, a French biotech company dedicated to developing novel therapeutic solutions for neurodegenerative diseases, today announced the closing of an 18 million euros ($20.9 million) Series A funding round. 2 December 2025
Latest In Brief for Alnylam Pharmaceuticals
Biotechnology
US clinical-stage genetic medicines company MeiraGTx Holdings saw its shares rise 15% to $9.74 pre-market today, as it announced a broad strategic collaboration in the area of ophthalmology with Eli Lilly. 10 November 2025
Latest Relevant Ones To Watch News
Further to the announcement under Rule 2.7 of the Irish Takeover Rules by Avadel and Alkermes on November 19, 2025, Danish CNS specialist Lundbeck confirms that it does not intend to make another offer for Avadel. 27 November 2025
20 November 2025
14 November 2025
30 October 2025
25 October 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze